MediciNova (NASDAQ:MNOV) shares are trading higher on Monday after the company announced an agreement with BioComoor for the joint development of a SARS-CoV-2 vaccine.
MediciNova is a biopharmaceutical company. It acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166 and MN-221.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases. It has the acquisition and development of small molecule therapeutics segment.
MediciNova shares were up 95% at $11 on Monday. The stock has a 52-week range between $13.25 and $2.79.